未登录

R

René Bruno

clinical pharmacology, genentech-roche, marseille, france

H指数:39

被引数:5,914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

基于模型TGI指标决策支持优化关键肿瘤试验的操作特性以解除试验限制

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-09-150

OAAI

Disease Modeling and External Model Evaluation Through Clinical Data Sharing Platform for HR+/HER2− Breast Cancer

HR+/HER2−乳腺癌的临床数据共享平台用于疾病建模和外部模型评估

cpt pharmacometrics systems pharmacology

IF0

2025-07-170

OAAI

Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-07-123

OAAI

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-04-172

OAAI

Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-10-253

OAAI

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-06-026

PRE

Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models

BRITISH JOURNAL OF CANCER

IF6.8

2023-02-1011

OA

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-01-299

OAAI

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

IF10.2

2023-01-0311

OA

Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-07-293

OA

Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study

IF3.7

2022-04-286

PRE

Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-02-0313

OA

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy

IF8.3

2022-02-0111

OAAI

Update to improve reproducibility and interpretability: A response to Machine Learning for Tumor Growth Inhibition

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-01-310

OAAI

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-09-2821

OA

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-08-2538

OAAI

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-08-0424

OAAI

Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-08-0318

OAAI

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

IF9.1

2021-06-1014

OAAI

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2021-04-016

OAAI